The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genmab (I)
Stock and Other Ownership Interests - Genmab (I)
Consulting or Advisory Role - Bayer; Genmab; Roche
Research Funding - Karyopharm Therapeutics; Puma Biotechnology
First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.
 
Malaka Ameratunga
No Relationships to Disclose
 
R Donald Harvey
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; Spectrum Pharmaceuticals; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); ArQule (Inst); AstraZeneca (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Rgenix (Inst); Sanofi (Inst); Takeda (Inst); Tesaro (Inst); Xencor (Inst)
 
Morten Mau-Sørensen
No Relationships to Disclose
 
Fiona Thistlethwaite
Consulting or Advisory Role - Achilles Therapeutics; Bristol-Myers Squibb; Evelo Therapeutics; GlaxoSmithKline; Octimet (Inst)
Research Funding - 3-V Biosciences (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
Other Relationship - iMatch
 
Ulf Forssmann
Employment - Genmab
Stock and Other Ownership Interests - Genmab
Patents, Royalties, Other Intellectual Property - Genmab
Travel, Accommodations, Expenses - Genmab
 
Manish Gupta
Employment - Genmab
 
Hrefna Johannsdottir
Employment - Genmab
 
Terrie Ramirez-Andersen
Employment - Ferring; Genmab; Novo Nordisk (I)
Stock and Other Ownership Interests - Genmab; Novo Nordisk; Novo Nordisk (I)
 
Mika Linette Bohlbro
Employment - Genmab
 
Nedjad Losic
Employment - Genmab
Stock and Other Ownership Interests - Genmab
 
Annette L. Ervin-Haynes
Employment - Genmab
 
Juanita Suzanne Lopez
Consulting or Advisory Role - Genmab; Novartis
Research Funding - Basilea (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Basilea; Roche/Genentech
 
Ignace Vergote
Consulting or Advisory Role - Advaxis (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Genmab (Inst); Immunogen (Inst); Millennium (Inst); MSD Belgium (Inst); Oncoinvent (Inst); PharmaMar (Inst); Roche (Inst); Roche (Inst); Sotio (Inst); Tesaro (Inst)
Research Funding - Amgen (Inst); Genmab (Inst); Oncoinvent (Inst); Roche (Inst); Stichting tegen kanker (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genmab; PharmaMar; Roche; Takeda; Tesaro